Kevin Grogan is the Managing Editor Europe at Commercial. He specializes in a diverse range of topics, including medicine and healthcare, alternative medicine, and business economics, with a particular focus on medical technology and diagnostics. Kevin's insights and analyses have been featured in Informa and Citeline.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kevin Grogan's articles predominantly focus on the healthcare and pharmaceutical industries, specifically covering press releases, private sector announcements, industry-specific news, and government announcements. His coverage also includes scientific topics related to drug development and biotech sectors.
Given this focus, Kevin is likely to be interested in receiving pitches that provide insights into new drug developments, clinical trials advancements, or significant healthcare deals. He may particularly appreciate access to exclusive data or expert commentary from industry professionals with insider knowledge of recent developments within the pharmaceutical field.
It's clear that Kevin has a strong interest in both scientific breakthroughs and business-related news within the pharmaceutical and biotech sectors. Therefore, individuals or organizations aiming to reach out should consider offering unique angles on these themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The Danish firm is hoping to challenge the dominance of Roche's blockbuster Hemlibra for hemophilia A with or without inhibitors.
Another approval in a niche market will help the PD-1 immunotherapy hit its £2bn peak sales target.
Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.
By: Kevin Grogan, Jul By
The BIA says that while the UK's private investors "remain the powerhouse of European fundraising," the public markets are lagging behind the continent's peers, never mind the US.
CEO Vas Narasimhan tells Scrip about the "new energy" driving the decade-old brand which is still the Swiss drugmaker's biggest seller by some distance.
Vas Narasimhan has reiterated concerns about what he perceives as the German government's innovation-unfriendly policies but says Japan is going in the right direction.
Approval for the breast cancer drug across the Atlantic is some way off. The UK major will be hoping for positive reimbursement talks in Europe so the oral SERD can start contributing to its coffers.
By: Jul By, Kevin Grogan
CEO Charl van Zyl tells Scrip that the firm's first or best-in-class pipeline is shaping up nicely.
The US firm is appealing a CHMP negative opinion on its Niemann-Pick disease type C therapy Meplyffa, stalling having hit a stumbling block in its efforts to enter a market which is larger than the US, where the ultra-rare lysosomal storage disorder drug is already approved.
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
